Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fasinumab

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

- PMLiVE

FDA clears Teva’s tardive dyskinesia drug Austedo

The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza

- PMLiVE

Regeneron drops RSV drug

Suptavumab failed to prevent the infections in re-term infants

- PMLiVE

Teva to cut 7000 jobs, close 15 manufacturing sites

Missed second-quarter sales expectations prompt the cutbacks

Sanofi reception

Solid start for Dupixent as Sanofi raises 2017 outlook

Analysts predict dermatology medicine could become a €5bn product if approved in other indications

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

- PMLiVE

NICE backs Teva’s Cinqaero for severe asthma

Ruling will allow it to compete with GSK's rival IL-5 inhibitor Nucala

AstraZeneca AZ

AZ on the slide again as CEO departure rumours bubble away

Soriot’s alleged departure makes investors nervous ahead of looming MYSTIC trial results

Sanofi reception

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

The IL-6 inhibitor will be used in combination with methotrexate for adults with RA

Sanofi reception

Sanofi/Regeneron’s Sarilumab cleared by FDA on second attempt

IL-6 inhibitor to treat adult RA patients

- PMLiVE

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links